Kontakt
Hoher Kontrast
Im Zentrum unserer Aktivitäten steht die kompetente Betreuung und Durchführung von mono- und multizentrischen nationalen und internationalen klinischen Studien in Zusammenarbeit mit einem lokalen Projektleiter am UKBB. Dabei haben wir Expertise im Bereich von akademischen und industriegesponserten Studien und stehen jeder Fachdisziplin des UKBB zur Verfügung.
Folgende Studien / Projekte werden aktuell von uns betreut:
Zur Zeit keine laufenden Studien.
Principle Investigator
Prof. Dr. med. Julia Bielicki
Total geplante Patient*innen
–
Design
Data Science-Implementation hybrid
Pediatric Personalized Research Network Switzerland (SwissPedHealth) – a Joint Pediatric National Data Stream
Principle Investigator
PD Dr. med. Julia Bielicki
Total geplante Patient*innen
–
Design
national, multicenter
SwissPedHealth Personalized Pediatric Primay care PREPP
Principle Investigator
Prof. Dr. med. Jan Bonhoeffer
Total geplante Patient*innen
–
Design
national, multicenter
SwissPandEmic&AmR Health Economy Awareness Detect
Subproject 2: UTI Risk Prediction Model
Principle Investigator
Prof. Dr. med. Julia Bielicki
Total geplante Patient*innen
–
Design
national, multicenter
SARS-CoV2 variants Evaluation in pRegnancy and paeDIatrics cohorts – An evaluation of school-based mass PCR testing in Baselland
Principle Investigator
Prof. Dr. med. Julia Bielicki
Total geplante Patient*innen
–
Design
population-based evaluation
Zur Zeit keine laufenden Studien.
Active one health surveillance in LMICs to monitor and predict Antimicrobial Resistance Using Metagenomics
Principle Investigator CH
Prof. Dr. med. Julia Bielicki
Total geplante Patient*innen
> 1000
Design
International, multicenter
Routine antibiotic prescription and resistance monitoring in primary care physicians: A nationwide pragmatic randomized controlled trial
Principle Investigator
PD Dr. med. Julia Bielicki
Total geplante Patient*innen
–
Design
population-based
A randomized controlled non-inferiority trial of placebo versus macrolide antibiotics for Mycoplasma pneumoniae infection in children with community-acquired pneumonia
Principle Investigator
PD Dr. med. Julia Bielicki
Total geplante Patient*innen
380
Design
National, multicenter
Optimised kangaroo care to support breastfeeding and healthy microbiome acquisition in very preterm infants (MINI-KAB) -a substudy of the multicentre, parallel cluster randomised NeoDeco study
Principle Investigator
Dr. med. Kerstin Jost
Total geplante Patient*innen
>5000
Design
international, multicenter
Optimising kangaroo care to reduce neonatal severe infection/sepsis and resistant bacterial colonisation among high-risk infants in neonatal intensive care: a pragmatic, multicentre, parallel cluster randomised hybrid implementation–effectiveness trial
Principle Investigator
Dr. med. Kerstin Jost
Total geplante Patient*innen
>5000
Design
International, multicenter
Restricted versus liberal fluid intake for prevention of bronchopulmonary dysplasia – RELIEF trial
Principle Investigator
Prof. Dr. med. Sven Schulzke
Total geplante Patient*innen
700
Design
National, multicenter
Orales Propanolol zur Prävention einer höhergradigen Frühgeborenen-Retinopathie
Principle Investigator
Prof. Dr. med. Sven Schulzke
Total geplante Patient*innen
–
Design
National, multicenter
Capillary versus venous blood test: Validation study for the optimization of clinical laboratory tests in pediatrics
Principle Investigator
Dr. med. Alexandra Goischke
Total geplante Patient*innen
100
Design
national, monocenter
A 6-month multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and PK/PD of an age-and body weight-adjusted oral finerenone regimen, in
addition to an ACEI or ARB, for the treatment of children, 6 months to <18 years of age, with chronic kidney disease and proteinuria
Principle Investigator
Dr. med. Alexandra Goischke
Total geplante Patient*innen
2
Design
International, multicenter
An 18-month, open-label, single-arm safety extension study of an age-and bodyweightadjusted oral finerenone regimen, in addition to an ACEI or ARB, for the treatment of children and young adults from 1 to 18 years of age with chronic kidney disease and proteinuria
Principle Investigator
Dr. med. Alexandra Goischke
Total geplante Patient*innen
2
Design
International, multicenter
Evaluation of Novel Biomarkers for Early Detection of Renal Injury in Children at increased risk to develop chronic kidney disease: a prospective study
Principle Investigator
Dr. med. Alexandra Goischke
Total geplante Patient*innen
418
Design
National, multicenter
Pilotstudy for Evaluation of new Biomarkers in Kids with Celiac Disease.
Principle Investigator
Dr. med. Patricia Dill
Total geplante Patient*innen
20
Design
national, monocenter
Paediatric Arteriopathy Steroid Aspirin High dose steroids in children with stroke and unilateral focal arteriopathy
Principle Investigator
Prof. Dr. med. Alexandre Datta
Total geplante Patient*innen
24 (4 in Basel)
Design
International, multicenter
Prognosis, treatment, and mechanisms in an international paediatric onset opsoclonus myoclonus ataxia syndrome (POOMAS) database and virtual biobank
Principle Investigator
Prof. Dr. med. Andrea Klein
Total geplante Patient*innen
Offenes Register
Design
International, multicenter
Effect of pulsatile GnRH therapy on cognition in Down syndrome
Principle Investigator
Dr. med. Mark Brotzmann
Total geplante Patient*innen
5–10
Design
national, multicenter
Studientitel
Swiss Primary Hypersomnolence and Narcolepsy Study
Principle Investigator
Prof. Dr. med. Alexandre Datta
Total geplante Patient*innen
(2-5 in Basel)
Design
National, multicenter
Observational study to understand acceptability of various available midazolam formulations (syrup, rectal suppository, oro-dispersible minitablet) in clinical practice
Principle Investigator
Dr. med. Svetlana Beglinger
Total geplante Patient*innen
70
Design
National, multicenter
Prospective pharmacologic characterization of a novel cytomegalovirus-infection prophylaxis (Letermovir) in Pediatric hematopoietic cell transplantation patients using endogenous Coproporphyrin (LetPeCo)
Principle Investigator
PD Dr. med. Tamara Diesch
Total geplante Patient*innen
15 Patient*innen, Basel 6-7, Genf 8
Design
Multicenter, national
Swiss Childhood cancer Survivor Study-Follow up, Follow Up- Lungengesundheit nach Krebs im Kindesalter
Principle Investigator
Prof. Dr. med. Nicolas von der Weid
Total geplante Patient*innen
60-80
Design
National, multicenter
Studie zur Untersuchung der Lungenentwicklung bei Kindern u. Jugendlichen während und nach Krebstherapie
Principle Investigator
Dr. med. Christina Schindera
Total geplante Patient*innen
150
Design
National, multicenter
Zur Zeit keine laufenden Studien.
Multicenter, open-label, efficacy, tolerability and pharmacokinetic study of subcutaneous Ixekizumab with Adalimumab reference arm in children with juvenile idiopathic arthritis subtypes of enthesitis- related arthritis (including juvenile-onset ankylosing spondylitis) and juvenile psoriatic arthritis.
Principle Investigator
Dr. med. Andreas Wörner
Total geplante Patient*innen
100 Patienten (5 Patienten in Basel)
Design
International, multicenter
20200105: A Phase 3, Open-Label, Multicenter, Randomized Study to evaluate the Efficacy and Safety of Romosozumab Compared with Bisphosphonates in Children and Adolescents with Osteogenesis Imperfecta
Principle Investigator
Dr. med. Andreas Wörner
Total geplante Patient*innen
100 Patienten (5 Patienten in Basel)
Design
International, multicenter
Patient and Public Involvement & Engagement
Principle Investigator
Prof. Dr. med. Julia Bielicki
Total geplante Patient*innen
–
Design
International, monocenter
Acne detection software
Principle Investigator
Prof. Dr. med. Alexander Navarini
eingeschlossene Patient*en
40 (20 in Basel)
Design
National, multicenter
Advanced Diagnostics for Enhanced Quality of Antibiotic Prescription in Respiratory Tract Infections in Emergency rooms
Principle Investigator
PD Dr. med. Julia Bielicki
eingeschlossene Patient*en
500 (75 in Basel)
Design
International, multicenter
Principle Investigator
Prof. Dr. med. Julia Bielicki
Total geplante Patient*innen
700 (112 in Basel)
Design
International, multicenter
Randomised Evaluation of COVID-19 Therapy (RECOVERY) in Children With PIMS-TS in Switzerland
Principle Investigator
PD Dr. med. Julia Bielicki
Studienende
76
Design
International, multicenter
A randomized, double-blind, Phase 3 study to investigate efficacy and safety of teplizumab compared with placebo in participants 1 to 25 years of age with recently diagnosed Stage 3 Type 1 Diabetes (T1D)
Principle Investigator
PD. Dr. med. Marie-Anne Burckhardt
Geplante Patient*innen
5
Design
international, multicentre, Phase 3
Sponsor
Sanofi-Aventis Recherche & Développement, 82 Avenue Raspail, 94250 Gentilly, FRANCE
PIPELINE-RSV trial: an adaptive platform trial to evaluate strategies for the prevention of RSV in infants
Principle Investigator
Prof. Dr. med. Julia Bielicki
Geplante Patient*innen
Design
international, multicentre
058 387 78 82 (Kosten werden über die Krankenkasse abgerechnet)
Bei Notfällen im Ausland rufen Sie die Notfallnummer Ihrer Krankenkasse an. Die Kontaktdaten finden Sie jeweils auf Ihrer Krankenkassenkarte.
145 (Gift- und Informationszentrum)
Universitäts-Kinderspital beider
Basel, Spitalstrasse 33
4056 Basel | CH
Tel. +41 61 704 12 12
© UKBB, 2025
Die Medgate Kids Line liefert schnell und unkompliziert medizinischen Rat, wenn es Ihrem Kind nicht gut geht. Rund um die Uhr steht Ihnen das medizinische Team unseres Partners Medgate telefonisch zur Verfügung.
Für Notfälle im Ausland: Rufen Sie die Notfallnummer Ihrer Krankenkasse an. Diese finden Sie jeweils auf Ihrer Krankenkassenkarte.
Mehr Informationen: Auf der Seite der Notfallstation finden Sie alles Wichtige zu Verhalten in Notfällen, typischen Kinderkrankheiten und Wartezeiten.
144 Ambulanz
145 Tox Info Suisse (Vergiftungen)
117 Polizei
118 Feuerwehr
Zu welchem Thema möchten Sie uns kontaktieren?
Für Lob oder Tadel nutzen Sie bitte das Feedback-Formular.